Prospective Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia with Inversion(16) by CBFβ/MYH11 RT-PCR: Implications for a Monitoring Schedule and for Treatment Decisions

References

• Bloomfield C. D., Lawrence D., Byrd J. C., Carroll A., Pettenati M. J., Tantravahi R., Patil S. R., Davey F. R., Berg D. T., Schiffer C. A., Arthur D. C., Mayer R J. Frequency of prolonged remission duration following high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173–4179
   PubMed Web of Science ®Google Scholar
• Strout M. P., Marcucci G., Caligiuri M. A., Bloomfield C D. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol 1999; 78: 251–264
   PubMed Web of Science ®Google Scholar
• Mrózek K., Heinonen K., de la Chapelle A., Bloomfield C. D. Clinical significance of cytogenetics in acute myeloid leukemias. Semin Oncol 1997; 24: 17–31
   PubMed Web of Science ®Google Scholar
• Mayer R. J., Davis R. B., Schiffer C. A., Berg D. T., Powell B. L., Schulman P., Omura G. A., Moore J. O., McIntyre O. R., Frei E., III. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Byrd J. C., Dodge R. K., Carroll A., Baer M. R., Edwards C., Stamberg J., Qumsiyeh M., Moore J. O., Mayer R. J., Davey E, Schiffer C. A., Bloomfield C D. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17: 3767–3775
   PubMed Web of Science ®Google Scholar
• Liu P., Tarlé S.A., Hajra A., Claxton D. F., Marlton P., Freedman M., Siciliano M. J., Collins F. S. Fusion between transcription factor CBFβ/PEBP2β and myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041–1044
   PubMed Web of Science ®Google Scholar
• Mitterbauer M., Laczika K., Novak M., Mitterbauer G., Hilgarth B., Pirc-Danoewinata H., Schwarzinger I., Haas O. A., Fonatsch C., Lechner K., Jaeger U. High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study. Am J Clin Pathol 2000; 113: 406–410
   PubMed Web of Science ®Google Scholar
• Langabeer S. E., Walker H., Gale R. E., Wheatley K., Burnett A. K., Goldstone A. H., Linch D. C. Frequency of CBFbeta/MYH11 fusion transcripts in patients entered into UK MRC AML trials. Br J Haemat 1997; 96: 736–739
   PubMed Web of Science ®Google Scholar
• Claxton D. F., Liu P., Hsu H. P., Marlton P., Hester J., Collins E, Deisseroth A. B., Rowley J. D., Siciliano M. J. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994; 83: 1750–1756
   PubMed Web of Science ®Google Scholar
• Poirel H., Radford-Weiss I., Rack K., Troussard X., Veil A., Valensi E, Picard E, Guesnu M., Leboeuf D., Melle J., Dreyfus E, Flandrin G., Macintyre E. Detection of chromosome 16 CBFβ-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995; 85: 1313–1322
   PubMed Web of Science ®Google Scholar
• Hébert J., Cayuela J. M., Daniel M. T., Berger R., Sigaux E. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood 1994; 84: 2291–2296
   PubMed Web of Science ®Google Scholar
• Evans P. A., Short M. A., Jack A. S., Norfolk D. R., Child J. A., Shiach C. R., Davies E, Tobal K., Liu Tin J. A., Morgan G J. Detection and quantitation of the transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia 1997; 11: 364–369
   PubMed Web of Science ®Google Scholar
• Laczika K., Novak M., Hilgarth B., Mitterbauer M., Mitterbauer G., Scheidel-Petrovic A., Scholten C., Thalhammer-Scherrer R., Brugger S., Keil E, Schwarzinger I., Haas O. A., Lechner K., Jaeger U. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. J Clin Oncol 1998; 16: 1519–1525
   PubMed Web of Science ®Google Scholar
• Costello R., Sainty D., Blaise D., Gastaut J. A., Gabert J. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBFβ/MYH11-positive acute myeloblastic leukemia (letter). Blood 1997; 89: 2222–2223
   PubMed Web of Science ®Google Scholar
• Marcucci G., Caligiuri M. A., Bloomfield C D. Defining the “absence” of the CBFβ/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: A call for definitions (letter). Blood 1997; 90: 5022–5025
   PubMed Web of Science ®Google Scholar
• Martinelli G., Ottaviani E., Testoni N., Montefusco V., Pastano R., Tura S. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFβ/MYH11 transcript. Haematologica 2000; 8: 552–555
   Google Scholar
• Liu Yin J. A. Detection of minimal residual disease in acute myeloid leukemia: methodologies, clinical and biological significance. British Journal of Haematology 1999; 106: 578–590
   PubMed Web of Science ®Google Scholar
• Elmaagacli A. H., Beelen D. W., Kroll M., Trzensky S., Stein C., Schaefer U. W. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 21: 159–166
   PubMed Web of Science ®Google Scholar
• Martin G., Barragan E., Bolufer P., Chillon P., Garcia-Sanz R., Gomez T., Brunei S., Gonzalez M., Sanz M. A. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFβ/MYH11 rearrangement. Haematologica 2000; 85: 699–703
   PubMed Web of Science ®Google Scholar
• Marcucci G., Caligiuri M. A., Maghraby E. A., Archer K. J., Dohner K., Schlenk R. F., Dohner H., Bloomfield C. D. Quantification of CBFβ/MYH11 transcripts in inv(16) acute myeloid leukemia (AML) by real time RT-PCR. Blood 1999; 94(Suppl. 1)740a
   Google Scholar
• Krauter J., Hoellge W., Wattjes M., Nagel S., Doden M., Krug U., Ganser A., Heil G. Real time PCR for the detection and quantification of CBFβ/Myh11 fusion transcripts in inv(16) positive AML. Blood 1999; 94(Suppl. 1)207b
   Google Scholar
• Krauter J., Hoellge W., Wattjes M., Nagel S., Ganser A., Heil G. Real time PCR for the detection and quantification of CBFβ/Myh11 fusion transcripts in inv(16) positive AML. Onkologie 1999; 23(Suppl. 7)95a
   Google Scholar
• Tobal K., Johnson P. R.E., Saunders M. J., Harrison C. J., Liu Yin J A. Detection of CBFβ/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol 1995; 91: 104–108
   PubMed Web of Science ®Google Scholar
• Sperr W. R., Piribauer M., Agis H., Mitterbauer M., Geissler K., Haas O. A., Fonatsch C., Jaeger U., Schwarzinger I., Thalhammer F, Valent P., Lechner K. Intermittent intermediate dose ARA-C as consolidation therapy for AML in the elderly. Blood 1998; 90(Suppl. 1)509a
   Google Scholar
• Mitterbauer G., Zimmer C., Fonatsch C., Haas O. A., Thalhammer-Scherrer R., Schwarzinger I., Kalhs P., Jaeger U., Lechner K., Mannhalter C. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR. Leukemia 1999; 13: 1519–1524
   PubMed Web of Science ®Google Scholar
• Kwok S., Higuchi R. Avoiding false positives with the PCR. Nature 1989; 339: 237–238
   PubMed Web of Science ®Google Scholar
• Mannhalter C., Koizar D., Mitterbauer G. Evaluation of RNA isolation methods and reference genes for RT-PCR analyses of rare target RNA. Clin Chem Lab Med 2000; 38: 171–177
   PubMed Web of Science ®Google Scholar
• ISCN. An International System for Human cytogenetic Nomenclature, F Mitelman. Basel, KargerSwitzerland 1995
   Google Scholar
• Pallisgaard N., Hokland P., Riishoj D. C., Pedersen B., Jorgensen P. Multiplex reverse transcription-polymerase chain reaction and chromosomal aberrations in acute myeloid leukemia. Blood 1998; 92: 574–588
   PubMed Web of Science ®Google Scholar
• Lo Coco E, Diverio D., Avvisati G., Petti M. C., Meloni G., Pogliani E., Biondi A., Rossi G., Carlo-Stella C., Selleri C., Martino B., Specchia G., Mandelli F. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229
   PubMed Web of Science ®Google Scholar